Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2015 · 10-Q
Revenue$7.00K$7.00K— vs Q1 2014 Net Income-$20.52M-$20.52MN/M vs Q1 2014 EPS Diluted-$8.61-$8.61— vs Q1 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
-$1,811,000
N/M
Operating Cash Flow-$1,787,000N/M Margins · derivedGross margin100.0%
Operating margin-25871.4%
Net margin-293085.7%
ended Mar 31, 2015 · filed May 14, 2015 · 44 d after period end